“Update on NuGenerex Immuno-Oncology (NGIO) divi
Post# of 36537
Acquisition plans for NGIO Merger with Company with Synergistic Platforms”
So just reading this, although I think it’s been posted before. I wonder if GNBT’s plan is to not buy a shell to reverse into, but rather merge with another company to go public immediately? If so, then the company we merge with will obviously have a piece of the new company. That would dilute our holdings, so will we shareholders have about 10% of the overall new company? If so, then we have a piece of their business so we don’t get diluted. If not, then we don’t have 10% and GNBT’s share of the new company will not be the same % either. Hopefully if they go this direction, then we get a piece of the WHOLE PIE.